Related Experiment Videos
Liquid ventilation in an infant with persistent interstitial pulmonary emphysema.
1Division of Neonatology, Careggi University Hospital, Florence, Italy. cdani@unifi.it
Journal of Perinatal Medicine
|May 10, 2001
Summary
Partial liquid ventilation (PLV) offers a promising treatment for infants with persistent interstitial pulmonary emphysema (PIPE), a severe lung condition. This innovative respiratory support improved infant outcomes without adverse effects, suggesting potential for increased survival.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Respiratory Physiology
Background:
- Persistent interstitial pulmonary emphysema (PIPE) is a rare, lethal neonatal lung disease with unknown causes.
- Conventional treatments often fail to manage severe cases of PIPE effectively.
Observation:
- A full-term infant diagnosed with diffuse persistent interstitial pulmonary emphysema (PIPE) was treated with partial liquid ventilation (PLV).
- Diagnosis was confirmed through clinical, radiological, and histological examinations.
Findings:
- Partial liquid ventilation (PLV) administered for 48 hours led to significant respiratory function improvement in the infant.
- No adverse effects were observed during or after the PLV treatment.
Implications:
- Partial liquid ventilation (PLV) may be a viable therapeutic option to extend survival in infants suffering from PIPE.
- PLV demonstrates potential as an effective respiratory support strategy for neonates with chronic lung disease.